Sales of AstraZeneca PLC's vaccine Vaxzevria may be dwindling but its COVID-19 antibody cocktail Evusheld is selling well and will continue to do so, especially if an improved version gets to market next year.
That is the view of CEO Pascal Soriot who spoke the media on 10 November as AstraZeneca presented a strong...







